Cozen O’Connor: Lukas, Aaron

Aaron Lukas, Ph.D.

Member

Washington, D.C.

(202) 912-4823

(202) 861-1905

Recent News:

13 Cozen O'Connor Attorneys Recognized as Washington, D.C. Super Lawyers and Rising Stars

The 2019 Washington, D.C, edition of Super Lawyers Magazine, published by Thomson Reuters, has named 13 Cozen O’Connor attorneys to its list of Super Lawyers and Rising Stars.

Aaron concentrates his practice in complex patent cases for clients in the pharmaceutical, biotechnology, and semiconductor industries.  

Aaron is a registered patent attorney and focuses his practice on the representation of generic pharmaceutical companies in Hatch-Waxman litigation. His practice also includes representing clients preparing patentability, infringement, and invalidity opinions, as well as preparing and prosecuting U.S. and foreign patent applications. Aaron has provided opinions and drafted and prosecuted patent applications in a wide range of high technology fields, including pharmaceuticals, therapeutic methods, nanotechnology, gene synthesis, recombinant DNA technology, diagnostic assays, and semiconductor devices. 

Aaron has research experience in organic chemistry, nanotechnology, and semiconductors. Prior to attending law school, Aaron was a senior research scientist at Air Products and Chemicals, Inc. where he researched next generation thin film precursors and deposition methods for use in flat panel displays, interconnects and other high tech applications (2001-2005). That research has resulted in 18 issued patents. Aaron's research experience also includes work as a graduate research assistant at Northwestern University's International Center for Nanotechnology and Department of Chemistry, where as a part of his doctoral research he synthesized and studied light-absorbing organic molecules for use as molecular switching devices (1996-2001). He is also a graduate of Georgetown Law, and earned bachelor's degrees in chemistry and humanities, cum laude, from Seattle University.

Experience

News

13 Cozen O'Connor Attorneys Recognized as Washington, D.C. Super Lawyers and Rising Stars

April 25, 2019

The 2019 Washington, D.C, edition of Super Lawyers Magazine, published by Thomson Reuters, has named 13 Cozen O’Connor attorneys to its list of Super Lawyers and Rising Stars.

Washington, D.C. Super Lawyers Recognizes 15 Cozen O'Connor Attorneys

May 15, 2018

Fourteen Cozen O’Connor attorneys have been named 2018 Super Lawyers or Rising Stars by Super Lawyers Magazine Washington, D.C. edition, published by Thomson Reuters.

11 Cozen O'Connor Attorneys Recognized as Washington, D.C. Super Lawyers and Rising Stars

May 15, 2017

Selection to Super Lawyers is based on peer nominations and evaluations are combined with independent research. Each candidate is evaluated on 12 indicators of peer recognition and professional achievement.

Cozen O’Connor Promotes 17 Attorneys to Membership

April 03, 2017

The management committee is pleased to welcome a particularly qualified group to membership, composed of outstanding attorneys who have demonstrated remarkable professionalism, leadership, dedication, and loyalty to the firm and the legal community at large.

Eleven Cozen O'Connor Attorneys Recognized as Washington, D.C., Super Lawyers and Rising Stars

April 27, 2015

Washington, D.C., April 27, 2015 – The 2015 Washington, D.C., edition of Super Lawyers Magazine, published by Thomson Reuters, has named 11 Cozen O’Connor attorneys to its annual list of Super Lawyers and Rising Stars.

Nine Cozen O’Connor Attorneys Recognized as Washington, D.C., Super Lawyers and Rising Stars

May 01, 2014

Washington, D.C., May 1, 2014 – The 2014 Washington, D.C., edition of Super Lawyers Magazine, published by Thomson Reuters, has named nine Cozen O’Connor attorneys to its list of Super Lawyers and Rising Stars.

Cozen O’Connor Continues Growth of IP Litigation Practice with Seven Partners, Two Associates from Duane Morris

April 16, 2012

Cozen O’Connor Continues Growth of IP Litigation Practice with Seven Partners, Two Associates from Duane Morris

Publications

Will the Supreme Court Help Biosimilars Meet Their Potential? [Bloomberg BNA's Pharmaceutical Law & Industry Report]

August 11, 2017

Aaron Lukas, a member of Cozen O'Connor's Intellectual Property department, discusses this topic in the Pharmaceutical Law & Industry Report.

Claim Construction at the Federal Circuit [Inside Counsel]

December 01, 2015

Aaron Lukas and Eric Choi, associates in Cozen O’Connor’s IP group, discuss claim construction at the federal circuit.

The Trans-Pacific Partnership and Its Effect On Biosimilars [Inside Counsel]

November 23, 2015

Aaron Lukas and Keri Schaubert, associates of Cozen O’Connor’s IP group, discuss the effect that the Trans-Pacific Partnership will have on the biopharmaceutical and biosimilar industry.

Inter Partes Review Has Been Incredibly Successful, So Why is the Patent Office Making Changes? [InsideCounsel]

October 08, 2015

Aaron Lukas and Carl Wischhusen discuss the advantages of inter partes review proceedings that have made them a routine tactic for defendants and the potential impact of new regulations recently proposed by the USPTO.

Will the Inventor of the Handheld Cash Register Ever Cash-In? [Inventors Digest]

December 15, 2014

Aaron Lukas, an associate in Cozen O'Connor's Intellectual Property Department, authored an article for Inventors Digest titled ‘Will the Inventor of the Handheld Cash Register Ever Cash-In?’ The article addresses recent rulings in cases involving CardSoft and Teva and changes to how patent validity is decided in patent litigation cases.

ESI: My Amex! Litigators and Clients Must Work Together to Reduce E-Discovery Costs [Westlaw Journal Computer & Internet]

May 19, 2014

Chad Stouffer and Aaron Lukas, associates in Cozen O'Connor's Intellectual Property Department, discuss various e-discovery solutions and how to implement a cost-effective discovery strategy.

IP: Compound Patents Take a Hit in Delaware District Court [Inside Counsel]

March 19, 2013

A recent decision from the Delaware District Court held that the composition of matter patent for the drug Baraclude was invalid as obvious. This opinion has drawn immediate attention because it is the first time that a lead compound obviousness challenge has succeeded in a district court since KSR v. Teleflex issued. What this means for inside counsel depends on which side of the aisle you are on, but regardless this decision may provide the beachhead for obviousness attacks where none existed before.

Events & Seminars

Past Events

Paragraph IV Disputes 2019

April 29, 2019 - New York, NY

8th Annual Summit on Biosimilars

June 12, 2017 - New York, NY

Education

  • Georgetown University Law Center, J.D., 2010
  • Northwest University, Ph.D., 2001
  • Seattle University, B.A., 1996
  • Seattle University, B.S., cum laude, 1996

Awards & Honors

Washington, DC Super Lawyers - Rising Star, Intellectual Property - 2014-2015, 2019

  • District of Columbia
  • United States Patent and Trademark Office
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Supreme Court